Journal
MOLECULAR CELL
Volume 65, Issue 3, Pages 476-+Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2016.12.010
Keywords
-
Categories
Funding
- Swiss National Science Foundation [31003A_149402, 31003A_163447]
- NCCR RNA Disease
- European Union [241985]
- Novartis Research Foundation through the FMI
- EMBO [ALTF 95-2015]
- European Commission [GA-2013-609409]
- FMI
- NIH Office of Research Infrastructure Programs [P40 OD010440]
- Swiss National Science Foundation (SNF) [31003A_149402, 31003A_163447] Funding Source: Swiss National Science Foundation (SNF)
- European Research Council (ERC) [241985] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The RNA-binding protein (RBP) LIN41, also known as LIN-41 or TRIM71, is a key regulator of animal development, but its physiological targets and molecular mechanism of action are largely elusive. Here we find that this RBP has two distinct mRNA-silencing activities. Using genome-wide ribosome profiling, RNA immunoprecipitation, and in vitro-binding experiments, we identify four mRNAs, each encoding a transcription factor or cofactor, as direct physiological targets of C. elegans LIN41. LIN41 silences three of these targets through their 30 UTRs, but it achieves isoform-specific silencing of one target, lin-29A, through its unique 50 UTR. Whereas the 30 UTR targets mab-10, mab-3, and dmd-3 undergo transcript degradation, lin-29A experiences translational repression. Through binding site transplantation experiments, we demonstrate that it is the location of the LIN41-binding site that specifies the silencing mechanism. Such position-dependent dual activity may, when studied more systematically, emerge as a feature shared by other RBPs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available